$WAT

KeyBanc analyst Paul Knight anticipates accelerating growth in the Life Sciences Tools & Services sector, with earnings reports from TMO and DHR starting October 21, 2026. The firm highlights potential revenue growth beats for several companies, including WST, DHR, RGEN, STVN, WAT, and TMO. Waters Corporation (WAT) has seen a 40% gain over six months, trading at $425 with a $41.8B market cap, though it appears overvalued relative to its Fair Value.

CellCarta, a global CRO laboratory, partnered with Waters Corporation to advance companion diagnostics (CDx) and flow cytometry. The collaboration combines CellCarta's clinical trial testing capabilities with Waters' standardized platforms. They aim to provide a coordinated path for biomarker strategy, clinical development, and global commercialization, focusing initially on flow cytometry-based programs.

Analysts adjusted price targets for several companies. Inspire Medical (INSP) raised to $97, Securitize (SECZ) to $13, Cleveland-Cliffs (CLF) to $17.48, Credo (CRDO) cut to $245, Colgate-Palmolive (CL) to $95, TTM (TTMI) to $175, Waters (WAT) to $515, Microsoft (MSFT) to $608, Ciena (CIEN) to $550, T-Mobile (TMUS) to $260.

Goldman Sachs raised its price target for Waters Corporation to $515 from $465, maintaining a Buy rating. The stock closed at $421.63, down 1.88% over 5 days but up 11% year-to-date. The adjustment is based on a weighted average of valuation, EPS revisions, and visibility metrics.

Analysts upgraded five companies: Barclays raised Sagimet Biosciences (SGMT) to Overweight, targeting $18. B of A upgraded Figure Technology (FIGR) to Neutral, targeting $49. UBS upgraded Illumina (ILMN) to Buy, targeting $260. Wells Fargo upgraded Martin Marietta (MLM) to Overweight, targeting $609. UBS also upgraded Waters (WAT) to Buy, targeting $490.

Bruker (BRKR) reported Q2 revenue of $838.5M, up 5.2% YoY but missing estimates by 1.9%. Its stock fell 7.3% post-results. Avantor (AVTR) beat expectations with $1.69B revenue, up flat YoY, and its stock rose 17.1%. Waters (WAT) saw 113% revenue growth but mixed guidance, with its stock up 10.3%. Bio-Techne (TECH) and Danaher (DHR) also reported earnings, with TECH flat and DHR up 5.7% post-results.

Morgan Stanley analysts believe Waters Corporation is well-positioned due to China's new clinical lab pricing rules, favoring its mass spectrometry and microbiology workflows. Danaher faces mixed impacts, with some revenue headwinds, while Thermo Fisher has limited exposure. The framework was finalized by China's National Healthcare Security Administration.

Waters Corporation (WAT), a $40.7B life sciences and diagnostics company, reported Q2 2026 adjusted EPS of $3.05 and revenue of $1.65B, exceeding expectations. The stock has risen 43% over 52 weeks, outperforming the S&P 500. Analysts expect 10.9% EPS growth for 2026, with a consensus 'Moderate Buy' rating and a mean price target of $438.43.

Waters Corp. (WAT) rose 1.8% to a 52-week high of $426.22 after Piper Sandler upgraded it to Overweight with a $480 price target, up from $400, citing expected demand recovery.

Piper Sandler upgraded Waters Corporation (WAT) to Overweight, raising its price target to $480 from $400. The company's stock is currently trading at $423.22, slightly above its GF Value™ of $411.65, indicating a 2.8% overvaluation. Waters Corporation has a GF Score™ of 95/100, reflecting strong growth and momentum but moderate financial strength. Insider activity shows recent selling of $1,442,930 worth of shares.